Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once weekly versus Norditropin once daily in short children with SGA, Turner syndrome, Noonan syndrome, or idiopathic short stature
CTR20230084Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of somapacitan in growth disorder, Turner syndrome (TS), Noonan syndrome, Idiopathic Short Stature (ISS), sponsored by Novo Nordisk. Started Mar 2023; status: active.
02
Drugs
somapacitan
03
Conditions
growth disorderTurner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on CTR20230084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230084.